A novel genetic strategy has shown early promise for treating Rett syndrome, a rare and severe neurodevelopmental disorder with no cure. Research published in Science Translational Medicine demonstrates that boosting levels of a crucial, but mutated, brain protein can reverse cellular defects, offering a potential new therapeutic pathway.
The disorder, which primarily affects girls and occurs in about 1 in 10,000 births, is caused by mutations in the MECP2 gene. This gene is essential for normal brain function, and its mutations lead to a regression in skills like speech and motor coordination. Critically, about 65% of patients have mutations that produce a MeCP2 protein that is partially functional but simply too scarce or weak. Previous work in mice had shown that increasing the amount of this mutant protein could reverse symptoms.
The breakthrough hinges on a nuanced understanding of how the MeCP2 protein is made. The brain naturally produces two versions, MeCP2-E1 and MeCP2-E2. Notably, Rett syndrome is only linked to mutations that disrupt the E1 version. The research team hypothesized that if they could block production of the E2 version, the cell's machinery would be redirected to produce more of the crucial E1 protein, even from the mutated gene. In tests on mice and human cells derived from patients, genetically deleting the unique component of the E2 recipe led to a 50% to 60% increase in total MeCP2 protein.
This increase had functional benefits. Patient-derived cells with the modification recovered part or all of their normal structure and electrical activity. The team then tested a synthetic molecule called a morpholino, designed to block E2 production. It successfully increased MeCP2 levels in mice, providing preclinical proof-of-concept for a drug-based approach.
While morpholinos themselves are not suitable for human therapy due to toxicity, the study lays vital groundwork. The authors suggest that similar, safer strategies, such as antisense oligonucleotide therapies already used for other neurological conditions, could be developed to harness this mechanism. This research offers a hopeful direction for a treatment that could ameliorate symptoms by precisely tuning the production of a fundamental brain protein.